THE IMPACT OF LIPID-LOWERING THERAPIES ON THE MANAGEMENT OF DYSLIPIDEMIA AND THE PREVENTION OF CARDIOVASCULAR EVENTS

Lipid-lowering therapies, such as PCSK9 inhibitors and bempedoic acid, are essential in the treatment of dyslipidemia, especially for patients who do not reach their LDL-C targets with statins.PCSK9 inhibitors can reduce LDL-C levels by up to 60% and have shown efficacy in preventing cardiovascular events in high-risk populations.However, their high cost limits access, generating debate about cost-effectiveness, especially in developing countries.Bempedoic acid offers an alternative for those who cannot tolerate statins, but its efficacy in cardiovascular events still needs more data.Long-term safety and affordability are key concerns as these therapies evolve.